Why Novartis (NVS) is a Top Value Stock for the Long-Term

Novartis (NVS) is highlighted as a top value stock, holding a Zacks #2 (Buy) Rank, an 'A' VGM Score, and a 'B' Value Style Score, supported by an attractive 13.86 forward P/E. Analysts have recently raised fiscal 2025 earnings estimates to $8.81 per share, reflecting a $0.12 increase and a historical average earnings surprise of +7.1%. The company's dominant pharmaceutical market position, bolstered by a strong drug portfolio and pipeline products such as Kesimpta and Pluvicto, reinforces NVS as a compelling investment opportunity.

Analysis

Novartis (NVS) presents a compelling case based on a combination of strong quantitative ratings and positive fundamental indicators. The company holds a Zacks #2 (Buy) Rank, supported by a top-tier 'A' VGM score and a 'B' for Value, signaling strength across multiple investment styles. The valuation appears attractive with a forward P/E ratio of 13.86. This positive outlook is further substantiated by forward-looking analyst activity; two analysts have revised their fiscal 2025 earnings estimates upwards in the last 60 days, lifting the Zacks Consensus Estimate by $0.12 to $8.81 per share. Historically, NVS has demonstrated an ability to outperform expectations, boasting an average earnings surprise of +7.1%. Fundamentally, the company's market position is secured by a diverse drug portfolio and a robust pipeline, with specific growth drivers identified as Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio, and Fabhalta, which are expected to fuel performance in key therapeutic areas and geographies.

Key Decisions for Investors

• Given the Zacks #2 (Buy) rank and favorable valuation metrics like a 13.86 forward P/E, investors with a value or GARP (Growth at a Reasonable Price) focus should consider NVS a strong candidate for their portfolios.
• Monitor the sales trajectory of key growth drugs such as Kesimpta and Pluvicto, as their continued commercial success is integral to achieving the upwardly revised earnings forecasts.
• Investors should watch for continued positive earnings estimate revisions, as the current bullish thesis is heavily dependent on this trend; any reversal could signal a change in the company's near-term outlook.